Antiarrhythmic therapy with flecainide in combination and comparison with propranolol

Area of Science:

• Cardiology
• Clinical Pharmacology

Background:

• Chronic ventricular arrhythmias pose a significant clinical challenge.
• Antiarrhythmic drug efficacy and interactions require thorough investigation.

Purpose of the Study:

• To evaluate the antiarrhythmic efficacy of flecainide and propranolol, alone and in combination, in patients with chronic ventricular arrhythmias.
• To assess the impact of these drugs on cardiac electrophysiology and patient-reported side effects.

Main Methods:

• Prospective crossover study involving 10 patients with chronic ventricular arrhythmias.
• Administration of flecainide (50mg tid) and propranolol (20mg tid) individually and combined.
• Monitoring included routine and 24-hour ECG, plasma drug concentrations, and side effect recording.

Main Results:

• Flecainide monotherapy significantly reduced ventricular premature complexes (38%) and couplets (75%), eliminating ventricular tachycardia.
• Propranolol monotherapy at the tested dose showed no antiarrhythmic effect.
• Combination therapy offered no additional benefit over flecainide alone, with a slight, non-significant increase in arrhythmias and a 25% increase in flecainide plasma concentration.

Conclusions:

• Flecainide is an effective antiarrhythmic agent for chronic ventricular arrhythmias at 50mg tid.
• Propranolol, at 20mg tid, demonstrated no significant antiarrhythmic effect in this patient group.
• Combined therapy with flecainide and propranolol did not enhance therapeutic benefits and slightly increased certain arrhythmia types, warranting caution.